- $394.95m
- -$58.86m
- $97.67m
- 51
- 30
- 45
- 37
Annual cashflow statement for Somalogic, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | -57 | -53 | -87.5 | -109 |
Depreciation | ||||
Non-Cash Items | 17.4 | 30.5 | 43.1 | -23.3 |
Unusual Items | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | -14.1 | -8.67 | 4.93 | 27.2 |
Change in Accounts Receivable | ||||
Change in Inventories | ||||
Change in Prepaid Expenses | ||||
Change in Other Assets | ||||
Change in Accounts Payable | ||||
Change in Accrued Expenses | ||||
Change in Other Liabilities | ||||
Other Operating Cash Flow | ||||
Cash from Operating Activities | -50.5 | -28.3 | -37 | -101 |
Capital Expenditures | -0.68 | -1.16 | -6.73 | -5.21 |
Purchase of Fixed Assets | ||||
Other Investing Cash Flow Items | 31.3 | -8.38 | -179 | 87.8 |
Acquisition of Business | ||||
Sale of Fixed Assets | ||||
Sale/Maturity of Investment | ||||
Purchase of Investments | ||||
Cash from Investing Activities | 30.7 | -9.54 | -185 | 82.5 |
Financing Cash Flow Items | 0 | 5 | 530 | 0 |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 0.144 | 189 | 497 | 5.18 |
Foreign Exchange Effects | ||||
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | -19.7 | 151 | 275 | -13 |